The propylthiouracil dilemma

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 5, 2012, Pages 402-407

  Glinoer, Daniel ^a   Cooper, David S ^b  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antithyroid drugs; drug induced liver injury; Graves' disease; hepatotoxicity; hyperthyroidism; propylthiouracil

Indexed keywords

CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE;

ACUTE LIVER FAILURE; AFRICAN AMERICAN; AMINOTRANSFERASE BLOOD LEVEL; CHILD CARE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; LIVER FUNCTION TEST; LIVER GRAFT; LIVER TOXICITY; PREGNANCY; REVIEW; THYROID CRISIS; THYROTOXICOSIS;

ADULT; AGE FACTORS; ANTITHYROID AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; LIVER FAILURE; MALE; METHIMAZOLE; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS; PROPYLTHIOURACIL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865961741     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283565b49     Document Type: Review

References (30)

1. Astwood EB, Vanderlaan WP. Treatment of hyperthyroidism with propylthiouracil. Ann Intern Med 1946; 25:813-821.
2. Astwood EB. The use of antithyroid drugs during pregnancy. J Clin Endocrinol Metab 1951; 10:1045-1056.
3. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905-917.
4. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986 - results of an international survey. Acta Endocrinol 1987; 115(Suppl. 285):1-23.
5. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70:1518-1524.
6. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010; 95:2227-2233.
7. Burch H, Burman K, Cooper DS. A 2011 survey of current practice in the management of Graves' disease. Eighty First Annual Meeting of the American Thyroid Association. 2011; Abstract 184.
8. Moore FD. Toxic manifestations of thiouracil therapy. JAMA 1946; 130:315-319.
9. Williams KV, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997; 82:1727-1733.
10. Kim H-J, Kim B-H, Han Y-S, Yang I, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001; 96:165-169.
11. Russo MW, Galanko JA, Shrestha R, et al. Liver transplant for acute liver failure from drug induced liver injury in the united States. Liver Transpl 2004; 10:1018-1023.
12. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94:1881-1882.
13. Rivkees SA. Sixty-three years and 715 days to the 'Boxed Warning': unmasking the propylthiouracil problem. Intern J Pediatr Endocrinol 2010; Article ID 658267:1-3.
14. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Intern J Pediatr Endocrinol 2009; Article ID 132041:1-8.
15. Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673-674.
16. FDA Statement (Medwatch Online) 2009. Information for healthcare professionals: Propylthiouracil-induced liver failure. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHealthcareProfessionals/ucm162701.htm. [Accessed 17 June 2010].
17. Malozowski S, Chiesa A. Propylthiouracil-induced hepatotoxicity and death. Hopefully, never more. J Clin Endocrinol Metab 2010; 95:3161-3163.
18. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17:456-520, Thyroid 2011; 21:593-646.
19. Liaw YF, Huang MJ, Fan KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. Ann Intern Med 1993; 118:424-428.
20. Carrion AF, Czul F, Arosemena LR, et al. Propylthiouracil-induced acute liver failure: role of liver transplantation. Intern J Endocrinol 2010; 2010:910636.
21. Morris CV, Goldstein RM, Cofer JB, et al. An unusual presentation of fulminant hepatic failure secondary to propylthiouracil therapy. Clin Transpl 1989; p. 311.
22. Ruiz JK, Rossi GV, Vallejos HA, et al. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003; 37:224-228.
23. Taylor P, Bhatt S, Gouni R, et al. A case of propylthiouracil-induced hepatitis during pregnancy. Eur Thyroid J 2012; 1:41-44.
24. Sequeira E, Wanyonyi S, Dodia R. Severe propylthiouracil-induced hepatotoxicity in pregnancy managed successfully by liver transplantation: a case report. J Med Case Rep 2011; 19:461-463.
25. Sisodia KP, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16:118-129.
26. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31:702-755.
27. Löllgen RM, Calza AM, Schwitzgebel VM, Pfister RE. Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero. J Pediatr Endocrinol Metab 2011; 24:215-218.
28. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007; 92 (Suppl.):S1-S47.
29. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081-1125.
30. Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe druginduced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Safety 2006; 15:221-229.